225 related articles for article (PubMed ID: 21298497)
1. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
Haas NB; Lin X; Manola J; Pins M; Liu G; McDermott D; Nanus D; Heath E; Wilding G; Dutcher J
Med Oncol; 2012 Jun; 29(2):761-7. PubMed ID: 21298497
[TBL] [Abstract][Full Text] [Related]
2. Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma.
Roubaud G; Gross-Goupil M; Wallerand H; de Clermont H; Dilhuydy MS; Ravaud A
Oncology; 2011; 80(3-4):214-8. PubMed ID: 21720184
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
Staehler M; Haseke N; Roosen A; Stadler T; Bader M; Siebels M; Karl A; Stief CG
Eur J Med Res; 2010; 15(7):287-91. PubMed ID: 20696639
[TBL] [Abstract][Full Text] [Related]
4. Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
Nanus DM; Garino A; Milowsky MI; Larkin M; Dutcher JP
Cancer; 2004 Oct; 101(7):1545-51. PubMed ID: 15378501
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy.
Dutcher JP; Nanus D
Med Oncol; 2011 Dec; 28(4):1530-3. PubMed ID: 20717755
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.
Park I; Lee HJ; Bae WK; Yoon S; Lee JL
Invest New Drugs; 2019 Dec; 37(6):1239-1246. PubMed ID: 31231787
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
Richey SL; Tamboli P; Ng CS; Lin E; Lim ZD; Araujo JC; Jonasch E; Sharma P; Pagliaro LC; Tannir NM
Am J Clin Oncol; 2013 Oct; 36(5):450-4. PubMed ID: 22706175
[TBL] [Abstract][Full Text] [Related]
8. Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
Pécuchet N; Bigot F; Gachet J; Massard C; Albiges L; Teghom C; Allory Y; Méjean A; Escudier B; Oudard S
Ann Oncol; 2013 Dec; 24(12):2963-7. PubMed ID: 24190963
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in combination with gemcitabine plus cisplatin chemotherapy in metastatic renal collecting duct carcinoma: A prospective, multicentre, single-arm, phase 2 study.
Sheng X; Cao D; Yuan J; Zhou F; Wei Q; Xie X; Cui C; Chi Z; Si L; Li S; Mao L; Lian B; Tang B; Yan X; Wang X; Kong Y; Dai J; Bai X; Zhou L; Guo J
Eur J Cancer; 2018 Sep; 100():1-7. PubMed ID: 29933095
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Tagawa ST; Milowsky MI; Jeske S; Mazumdar M; Kung S; Sung M; Lehrer D; Matulich D; Selzer J; Wright JJ; Nanus DM
Am J Clin Oncol; 2011 Oct; 34(5):443-8. PubMed ID: 20881475
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.
Porta C; Zimatore M; Imarisio I; Natalizi A; Sartore-Bianchi A; Danova M; Riccardi A
Cancer; 2004 May; 100(10):2132-8. PubMed ID: 15139055
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
Michaelson MD; McKay RR; Werner L; Atkins MB; Van Allen EM; Olivier KM; Song J; Signoretti S; McDermott DF; Choueiri TK
Cancer; 2015 Oct; 121(19):3435-43. PubMed ID: 26058385
[TBL] [Abstract][Full Text] [Related]
13. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Jonasch E; Lal LS; Atkinson BJ; Byfield SD; Miller LA; Pagliaro LC; Feng C; Tannir NM
BJU Int; 2011 Mar; 107(5):741-747. PubMed ID: 21355978
[TBL] [Abstract][Full Text] [Related]
14. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
15. Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Bellmunt J; Trigo JM; Calvo E; Carles J; Pérez-Gracia JL; Rubió J; Virizuela JA; López R; Lázaro M; Albanell J
Lancet Oncol; 2010 Apr; 11(4):350-7. PubMed ID: 20163987
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
[TBL] [Abstract][Full Text] [Related]
17. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
Oudard S; Banu E; Vieillefond A; Fournier L; Priou F; Medioni J; Banu A; Duclos B; Rolland F; Escudier B; Arakelyan N; Culine S;
J Urol; 2007 May; 177(5):1698-702. PubMed ID: 17437788
[TBL] [Abstract][Full Text] [Related]
18. Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features.
McGregor BA; McKay RR; Braun DA; Werner L; Gray K; Flaifel A; Signoretti S; Hirsch MS; Steinharter JA; Bakouny Z; Flippot R; Wei XX; Choudhury A; Kilbridge K; Freeman GJ; Van Allen EM; Harshman LC; McDermott DF; Vaishampayan U; Choueiri TK
J Clin Oncol; 2020 Jan; 38(1):63-70. PubMed ID: 31721643
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin and ifosfamide in patients with metastatic sarcomatoid renal cell carcinoma: a phase II study of the Genitourinary Group of the French Federation of Cancer Centers.
Escudier B; Droz JP; Rolland F; Terrier-Lacombe MJ; Gravis G; Beuzeboc P; Chauvet B; Chevreau C; Eymard JC; Lesimple T; Merrouche Y; Oudard S; Priou F; Guillemare C; Gourgou S; Culine S;
J Urol; 2002 Sep; 168(3):959-61. PubMed ID: 12187199
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer.
Neri B; Doni L; Gemelli MT; Fulignati C; Turrini M; Di Cello V; Dominici A; Maleci M; Mottola A; Ponchietti R; Raugei A; Valsuani G; Cini G
J Urol; 2002 Sep; 168(3):956-8. PubMed ID: 12187198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
